Image credit- shutterstock
Hangzhou Sciwind Biosciences has announced a strategic commercialisation collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist.
Under the agreement, Pfizer will obtain exclusive commercialisation rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China.
Sciwind Biosciences will remain the Marketing Authorisation Holder and will be responsible for research and development, registration, manufacturing, and supply of the product.
Under the terms of the agreement, Sciwind Biosciences is eligible to receive up to $495 million in upfront, regulatory and sales milestone payments.
Ecnoglutide was independently developed by Sciwind Biosciences and is a new–generation cAMP–biased GLP–1 receptor agonist. It is designed to provide more precise treatment options for patients with type 2 diabetes and long–term weight management needs. With its unique biased signaling mechanism, Ecnoglutide injection has demonstrated a strong efficacy and safety profile across multiple clinical studies, achieving in Chinese patients 15.1% placebo-adjusted weight loss, 92.8% of patients attaining clinically meaningful weight loss, and over 80% of patients achieving HbA1c levels below 7.0%.
Ecnoglutide injection was approved by China's National Medical Products Administration (NMPA) in January 2026 for the treatment of adult type 2 diabetes, and its marketing authorisation application for adult chronic weight management has been accepted by China's NMPA.
